BTMD vs EVAX vs NUVB vs HIMS

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -2. 5% for biote Corp. (BTMD). biote Corp. (BTMD) offers the better valuation at 2. 8x trailing P/E, making it the more compelling value choice. Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, biote Corp.

(BTMD) is the cheapest at 2. 8x versus Hims & Hers Health, Inc. at 50. 3x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -98. 8% for Evaxion Biotech A/S (EVAX). Over 10 years, the gap is even starker: HIMS returned +188. 5% versus EVAX's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Evaxion Biotech A/S (EVAX) is the lower-risk stock at 1.

29β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 92% more volatile than EVAX relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -2. 5% for biote Corp. (BTMD). On earnings-per-share growth, the picture is similar: biote Corp. grew EPS 703. 5% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

biote Corp.

(BTMD) is the more profitable company, earning 14. 1% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 14. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTMD leads at 18. 5% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — EVAX leads at 99. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVB: 157.

3% to $12. 40.

In this comparison, BTMD (2.

3% yield) pays a dividend. EVAX, NUVB, HIMS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, biote Corp.

(BTMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (2. 3% yield). Nuvation Bio Inc. (NUVB) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BTMD: -78. 3%, NUVB: -52. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BTMD is a small-cap deep-value stock; EVAX is a small-cap high-growth stock; NUVB is a small-cap high-growth stock; HIMS is a small-cap high-growth stock. BTMD pays a dividend while EVAX, NUVB, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.